Orchard Therapeutics’ $150 Million Series C Round Funding

Cooley advised Orchard Therapeutics on its oversubscribed $150 million Series C financing.

According to Orchard, the funding will be used to progress its three most advanced clinical programs towards registration and commercialization. The funding will also support the clinical and preclinical development of the company’s rare disease gene therapy pipeline.

Deerfield Management led the financing with significant new investments from RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management, ArrowMark Partners, Sphera Global Healthcare, Medison Ventures, Driehaus Capital Management and Ghost Tree Capital Group, as well as additional US-based healthcare funds.

Orchard is a fully integrated commercial-stage biotechnology company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies.

Cooley advised with a team including Stephen Rosen (Picture), Tom Goodman, Mark Jones and Shehzad Akram.

Involved fees earner: Stephen Rosen – Cooley LLP; Tom Goodman – Cooley LLP; Mark Jones – Cooley LLP;

Law Firms: Cooley LLP;

Clients: Orchard Therapeutics;